RecruitingPhase 1Phase 2NCT06360601
Intravenous Labetalol Versus Hydralazine in Preeclampsia
The Effect of Intravenous Infusion of Labetalol Versus Hydralazine on Cerebral Hemodynamics of Preeclampsia Patients Prospective Randamized Study
Sponsor
Tanta University
Enrollment
40 participants
Start Date
Apr 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome
Eligibility
Sex: FEMALEMin Age: 25 YearsMax Age: 45 Years
Inclusion Criteria1
- patient with clinical diagnosis of sever preeclampsia
Exclusion Criteria2
- Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLabetalol Injection
Labetalol intravenous infusion 20ml/hr
DRUGHydrALAZINE Injection
Hydralazine intravenous infusion 5mg/hr
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06360601